Repare Therapeutics Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
179
- Stock Symbol
-
RPTX
- Share Price
-
$1.14
- (As of Tuesday Closing)
Repare Therapeutics General Information
Description
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
Contact Information
Website
www.reparerx.comCorporate Office
- 7210 Frederick-Banting
- Suite 100, Saint Laurent
- Montreal, Quebec H4S 2A1
- Canada
Corporate Office
- 7210 Frederick-Banting
- Suite 100, Saint Laurent
- Montreal, Quebec H4S 2A1
- Canada
Repare Therapeutics Stock Performance
As of 18-Mar-2025, Repare Therapeutics’s stock price is $1.14. Its current market cap is $48.5M with 42.5M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.14 | $1.14 | $1.06 - $5.52 | $48.5M | 42.5M | 343K | -$2.00 |
Repare Therapeutics Financials Summary
As of 31-Dec-2024, Repare Therapeutics has a trailing 12-month revenue of $53.5M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | (121,180) | (121,180) | 61,398 | 252,795 |
| Revenue | 53,477 | 53,477 | 51,133 | 131,830 |
| EBITDA | (91,719) | (91,719) | (114,562) | (17,553) |
| Net Income | (84,689) | (84,689) | (93,796) | (29,047) |
| Total Assets | 176,506 | 176,506 | 253,901 | 364,075 |
| Total Debt | 1,933 | 1,933 | 3,410 | 5,428 |
Repare Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Repare Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Repare Therapeutics Comparisons
Industry
Financing
Details
Repare Therapeutics Competitors (91)
One of Repare Therapeutics’s 91 competitors is iTeos Therapeutics, a Formerly VC-backed company based in Watertown, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| iTeos Therapeutics | Formerly VC-backed | Watertown, MA | ||||
| ImmunityBio | Formerly VC-backed | San Diego, CA | ||||
| Sutro Biopharma | Formerly VC-backed | South San Francisco, CA | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland |
Repare Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Repare Therapeutics Patents
Repare Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230348456-A1 | Quinazolinones, pharmaceutical compositions containing the same, and methods of using the same | Pending | 29-Apr-2022 | ||
| EP-4504208-A1 | Methods of using atr inhibitors | Pending | 07-Apr-2022 | ||
| AU-2023224519-A1 | Polo-like kinase 4 (plk4) inhibitors, pharmaceutical compositions, methods of preparation and uses thereof | Pending | 23-Feb-2022 | ||
| EP-4482833-A1 | Polo-like kinase 4 (plk4) inhibitors, pharmaceutical compositions, methods of preparation and uses thereof | Pending | 23-Feb-2022 | ||
| US-20230142913-A1 | Tricyclic heteroarenes, pharmaceutical compositions containing the same, and methods of using the same | Pending | 06-Oct-2021 | C07D471/14 |
Repare Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Repare Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Repare Therapeutics ESG
Risk Overview
Risk Rating
Updated December, 14, 2022
31.93 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 16,216
Rank
Percentile
Pharmaceuticals
Industry
of 921
Rank
Percentile
Pharmaceuticals
Subindustry
of 452
Rank
Percentile
Repare Therapeutics FAQs
-
When was Repare Therapeutics founded?
Repare Therapeutics was founded in 2016.
-
Where is Repare Therapeutics headquartered?
Repare Therapeutics is headquartered in Montreal, Canada.
-
What is the size of Repare Therapeutics?
Repare Therapeutics has 179 total employees.
-
What industry is Repare Therapeutics in?
Repare Therapeutics’s primary industry is Drug Discovery.
-
Is Repare Therapeutics a private or public company?
Repare Therapeutics is a Public company.
-
What is Repare Therapeutics’s stock symbol?
The ticker symbol for Repare Therapeutics is RPTX.
-
What is the current stock price of Repare Therapeutics?
As of 18-Mar-2025 the stock price of Repare Therapeutics is $1.14.
-
What is the current market cap of Repare Therapeutics?
The current market capitalization of Repare Therapeutics is $48.5M.
-
What is Repare Therapeutics’s current revenue?
The trailing twelve month revenue for Repare Therapeutics is $53.5M.
-
Who are Repare Therapeutics’s competitors?
iTeos Therapeutics, ImmunityBio, Sutro Biopharma, Sorrento Therapeutics, and CRISPR Therapeutics are some of the 91 competitors of Repare Therapeutics.
-
What is Repare Therapeutics’s annual earnings per share (EPS)?
Repare Therapeutics’s EPS for 12 months was -$2.00.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
